# Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)

> **NCT01814722** · — · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 63 (actual)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01814722
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2012-11-09
- **Primary completion:** 2013-10-31
- **Final completion:** 2013-10-31
- **Target enrollment:** 63 (ACTUAL)
- **Why stopped:** The trial was terminated early due to slow recruitment.
- **Last updated:** 2017-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01814722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01814722, "Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01814722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*